Results 71 to 80 of about 22,889 (244)

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Molecular signatures of xenograft colorectal cancer in mice treated with topotecan: A mass spectrometry-based study

Toxicology Reports
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, yet it continues to have a low survival rate, largely due to the lack of effective treatments.
Yousra A. Hagyousif, Ruba A. Zenati, Nelson C. Soares, Hamza M. Al-Hroub, Farman Matloob Khan, Rizwan Qaisar, Rifat Hamoudi, Raafat El-Awady, Ahmad Y. Abuhelwa, Wafaa Ramadan, Waseem El-Huneidi, Eman Abu-Gharbieh, Karem H. Alzoubi, Yasser Bustanji, Mohammad H. Semreen   +14 more
doaj   +1 more source

Pharmacologic topoisomerase-I inhibition causes DNA damage and mortality in activated CD4+ T cells

Genetics & Applications, 2018
Topoisomerase-I is required for DNA replication. It acts by preventing torsional stress caused by DNA winding during replication fork progression.  Topoisomerase-I inhibitors are widely used in many cancer therapies, in light of their anti-proliferative ...
Mia Stanić, Iart Luca Shytaj, Marina Lusic   +2 more
doaj   +3 more sources

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet Oncology, 2018
BACKGROUND Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum ...
R. Chekerov, F. Hilpert, S. Mahner, A. El-Balat, P. Harter, N. de Gregorio, C. Fridrich, S. Markmann, J. Potenberg, R. Lorenz, G. Oskay-Oezcelik, Marcus Schmidt, P. Krabisch, H. Lueck, R. Richter, E. Braicu, A. du Bois, J. Sehouli   +17 more
semanticscholar   +1 more source

Plasma and tumor topotecan pharmacokinetics (PK).

, 2012
A, Plasma topotecan PK. Abcg2−/− animals, carrying ABCG2-positive tumor T1 (Fig. 2C), were treated with either vehicle +0.5 mg topotecan (green line) or 10 mg Ko143+0.5 mg topotecan (red line) per kg body weight and plasma was collected at 15, 30, 60, 90
Sven Rottenberg (135593), Jos Jonkers (13239), Wendy Sol (135571), Serge A. L. Zander (135568), Lee Greenberger (135576), Piet Borst (8809), Yixian Zhang (135581), Olaf van Tellingen (135587)   +7 more
core   +1 more source

The Development of Tyrosyl-DNA Phosphodiesterase 1 Inhibitors. Combination of Monoterpene and Adamantine Moieties via Amide or Thioamide Bridges [PDF]

, 2019
Eleven amide and thioamide derivatives with monoterpene and adamantine substituents were synthesised. They were tested for their activity against the tyrosyl-DNA phosphodiesterase 1 DNA (Tdp1) repair enzyme with the most potent compound 47a, having an ...
Reynisson
core   +1 more source

Duocarmycin‐Bearing Antibody‐Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL‐4 Xenograft Model

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Antibody–drug conjugates (ADCs) have demonstrated superior clinical outcomes in patients with HER2‐positive advanced breast cancer compared with previous treatment modalities. However, resistance and treatment‐limiting toxicities frequently emerge during repeated administration, underscoring an unmet need for strategies to overcome ADC failure.
Toshiya Tanaka, Akira Sugiyama, Juri Sakata, Toshifumi Tatsumi, Hiroto Katoh, Keisuke Maeda, Yuya Inagaki, Takefumi Yamashita, Takeshi Kawamura, Mayu Kuratani, Taiki Nakano, Masazumi Ishii, Mai Miura, Wakana Kamiya, Yuko Shiratori, Hisato Kitanoya, Michael Chansler, Naoki Harada, Masayuki Tsuchiya, Tsuyoshi Osawa, Shumpei Ishikawa, Tatsuhiko Kodama, Kenzo Yamatsugu, Hidetoshi Tokuyama, Motomu Kanai   +24 more
wiley   +1 more source

Image‐guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF‐labelled lipids and topotecan to visualise the effects of hyperthermia in tumours

Journal of Controlled Release, 2018
Image guided drug delivery using imageable thermosensitive liposomes (iTSLs) and high intensity focused ultrasound (FUS or HIFU) has attracted interest as a novel and non‐invasive route to targeted delivery of anti‐cancer therapeutics.
M. Centelles, Michael Wright, P. So, Maral Amrahli, X. Y. Xu, J. Stebbing, Andrew D. Miller, W. Gedroyc, M. Thanou   +8 more
semanticscholar   +1 more source

Topotecan lacks third space sequestration [PDF]

, 2000
The objective of this study was to determine the influence of pleural and ascitic fluid on the pharmacokinetics of the antitumor camptothecin derivative topotecan.
Loos, W.J. (Walter), Jonge, M.J.A. (Maja) de, de Jonge, Maja, Gelderblom, AJ, Verweij, J. (Jaap), Sparreboom, A, Verweij, Jaap, Gelderblom, A.J. (Hans), Sparreboom, A. (Alex), Loos, Walter   +9 more
core